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Abstract
Introduction: The most serious COVID‐19 deriving from severe acute respiratory
syndrome coronavirus 2 causes a cytokine release storm and it is associated with
worse outcomes. In COVID‐19 patients, interleukin‐6 (IL‐6) levels are significantly
elevated. Blocking IL‐6 preliminarily resulted in the improvement of this hyperin-
flammatory state. It is unknown which patients could require higher doses of toci-
lizumab to get out of the cytokine storm.
Materials and Methods: Twenty‐four patients affected by COVID‐19 pneumonia
were included. All the patients underwent tocilizumab 8mg/kg intravenously and
were tested for serum IL‐6 24 to 48 hours before and 12 to 48 hours after tocili-
zumab infusion. Comparisons between survivors and nonsurvivors were performed.
Results: Eighteen patients were discharged, while six patients died, with no clinical
or laboratory differences between the two groups at baseline. IL‐6 was not different
at baseline (P = .41), while 24 to 48 hours post‐tocilizumab IL‐6 serum levels were
significantly higher in nonsurvivors than in survivors (2398.5 [430.5‐9372] vs 290.5
[58.5‐1305.5] pg/mL, P = .022). Serum IL‐6 post‐tocilizumab showed a good pre-
dictive ability to discriminate survivors from nonsurvivors (area under the curve,
0.815; 95% confidence interval, 0.63‐0.99, P = .02).
Conclusion: Repeated measurement of the serum level of IL‐6 early after tocilizu-
mab may distinguish nonsurvivors from survivors and support the choice of deeper
targeting IL‐6 in COVID‐19 pneumonia.
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1 | INTRODUCTION
At the end of 2019, a novel coronavirus was identified as the cause of
a cluster of pneumonia cases in Wuhan, China. It rapidly spread,
resulting in an epidemic throughout China, followed by an increasing
number of cases in other countries throughout the world. In February
2020, the World Health Organization designated the disease as
COVID‐19, which stands for coronavirus disease 2019.1 The virus
that causes COVID‐19 is designated severe acute respiratory syn-
drome coronavirus 2 (SARS‐CoV‐2).
Some patients with severe COVID‐19 have laboratory evidence
of an exuberant inflammatory response, similar to cytokine release
syndrome, with persistent fever, elevated inflammatory markers (eg,
D‐dimer, ferritin), and elevated pro‐inflammatory cytokines, such as
interleukin‐6 (IL‐6) and IL‐1; these laboratory abnormalities have
been associated with critical and fatal illnesses.2‐5
Treatments selectively targeting the downstream inflammation
have recently shown some effectiveness in the most critically ill
patients.6‐8 Serum IL‐6 levels are significantly higher in patients
severely ill and needing tocilizumab than in patients recovering with
the standard of care for COVID‐19 pneumonia,9 and serum IL‐6
levels could effectively help the therapeutic choice of the clinicians.7‐9
Protocols on the efficacy and safety of intravenous tocilizumab for
COVID‐19 include the possibility of a second infusion at 12 to 24 hours
from the first one in patients with no adequate response.6 However,
clinicians often find this choice difficult in the absence of objective
laboratory parameters, which could early support the clinical choice for
a second infusion of tocilizumab. To answer this unmet need, a cohort of
patients undergoing tocilizumab for COVID‐19 pneumonia was studied
by looking at the serum IL‐6 levels before and soon after tocilizumab (ie,
within 48 hours from the first infusion), in survivors and nonsurvivors.
The serum levels of IL‐6 were significantly higher in patients dying than
in survivors, thus supporting the early dosage (ie, by 24‐48 hours from
tocilizumab infusion) of IL‐6 as a useful biomarker for subsequent
therapeutic choice.
2 | MATERIALS AND METHODS
Twenty‐four patients affected by COVID‐19 pneumonia were in-
cluded in this study (Table 1). All these patients underwent tocili-
zumab 8mg/kg intravenously for COVID‐19 pneumonia and all of
them were tested for serum IL‐6 24 to 48 hours before and within
48 hours after tocilizumab infusion. Only one of them received two
tocilizumab infusions 2 days apart.
Serum IL‐6 was measured by CE_IVD electrochemiluminescence
immunoassay (Elecsys IL‐6, Cobas, physiological range <7 pg/mL).7
Variables were reported as mean and standard deviation or
median and interquartile range (IQR), as appropriate, or frequency
rates and percentages if categorical; consequently, comparisons
between survivors and nonsurvivors were made by parametric tests
(t test for two independent samples) or no parametric tests (Mann‐
Whitney test) for continuous variables. Proportions were compared
by χ2 test or Fisher's exact test. For unadjusted comparisons, a two‐
sided α of less than .05 was considered statistically significant. A
receiver operating characteristic curve (ROC curve) was made to
TABLE 1 Main comparisons between
groups at hospital admission
Feature Survivors (N = 18) Nonsurvivors (N=6) P value
Age, y 65.8 ± 8.2 68.8 ± 9.4 .45
Gender, male, % 15 (83.3) 4 (66.7) .1
Days from onset to tocilizumab 8.5 ± 3.6 7.7 ± 4.1 .65
Weight, kg 84.1 ± 11.7 88.7 ± 15.1 .47
Hypertension, % 10 (55.6) 4 (66.7) 1.0
Charlson's index ≥ 2, % 3 (16.7) 0 .55
Antiviralsa, % 18 (100) 6 (100) ‐
Antimalarialsb, % 17 (94.4) 6 (100) 1.0
Glucocorticoidsc, % 5 (27.8) 3 (50) .36
LMWH (%) 13 (72.2) 4 (66.7) 1.0
Antibioticsd, % 14 (77.8) 5 (83.3) 1.0
WBC count, cells/µL 6221.2 ± 2435.1 6761.7 ± 4395.9 .71
Neutrophil count, cells/µL 5332.3 ± 2524.3 5623.3 ± 4190.8 .85
Lymphocytes, cells/µL 782.3 ± 355.9 711.7 ± 300.2 .68
Neutrophil/lymphocyte ratio 8.6 ± 5.4 10.2 ± 9.8 .72
Platelet count, cells/µL 174 187.5 ± 56 520.5 179 500 ± 51 960.6 .84
CRP, mg/L 145.3 ± 93.5 176 ± 95.6 .49
Procalcitonin, ng/mL 0.14 (0.07‐0.28) 0.28 (0.07‐0.75) .45
LDH, IU/L 726.6 ± 361.2 707 ± 299.5 .91
IL‐6, pg/mL 63.5 (50.7‐140) 171 (30.5‐626.5) .41
Abbreviations: CRP, C‐reactive protein; IL‐6, interleukin‐6; LDH, lactate dehydrogenase; LMWH, low
molecular weight heparin; WBC, white blood cells.
aLopinavir/ritonavir (L/R) or darunavir/cobicistat (D/C); remdesivir as second‐ or third‐line treatment.
bHydroxychloroquine or chloroquine.
cGlucocorticoids were always administered intravenously at the dose of 1mg/kg of
methylprednisolone in the first 2 days, then steroids were tapered and finally suspended in 7 days.
dAs prophylactic treatment, before tocilizumab therapy.
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identify the optimal cut‐off value for serum IL‐6 post‐tocilizumab that
was able to distinguish survivors and nonsurvivors. Ethical approval
for this study was given by “Comitato Etico Unico Regionale (CEUR),”
with the following registration number: CEUR‐2020‐Os‐102. The
study was conducted in accordance with the ethical principles of the
Helsinki Declaration. Patients' consent for using data for research
purpose was obtained at the time of hospital admission.
3 | RESULTS
Eighteen patients recovered and were discharged, while six patients
died. There were no differences between the two groups regarding
sex, age, weight, time to tocilizumab infusion from onset, Charlson's
index, and other clinical and laboratory baseline features as reported
in Table 1.
Notably, there was no difference between the two groups as
regards baseline IL‐6 levels (P = .41) (Table 1), while 24 to 48 hours
post‐tocilizumab, IL‐6 serum levels were significantly higher in non-
survivors than in survivors (2398.5 [430.5‐9372] vs 290.5 [58.5‐
1305.5] pg/mL, P = .022). In addition, the C‐reactive protein (CRP)
level was significantly higher in nonsurvivors than in survivors
(114.5 ± 83.6 vs 54.5 ± 34.9 pg/mL, P = .04), while procalcitonin did
not differ (0.69 [0.36‐1.13] vs 0.07 [0.04‐0.92] ng/mL, P = .21). Lac-
tate dehydrogenase, total white blood cell count, lymphocyte count,
and platelet count did not differ between survivors and nonsurvivors
early after tocilizumab (data not shown). The course of serum IL‐6,
CRP, and procalcitonin before and after tocilizumab in survivors and
nonsurvivors is depicted in Figure 1.
Serum IL‐6 post‐tocilizumab showed a good predictive ability to
discriminate survivors from nonsurvivors (area under the curve,
0.815; 95% confidence interval, 0.63‐0.99, P = .02), the value of
442.5 pg/mL being the discriminant between the two groups, with a
sensitivity of 0.83 and a specificity of 0.67. The cut‐off value of
336.5 pg/mL yielded a sensitivity of 1.0 and a specificity of 0.56. The
only patient who received two subsequent tocilizumab infusions re-
covered from COVID‐19 and showed the following values of serum
IL‐6: 130 pg/mL before tocilizumab, 433 pg/mL 24 hours after, and
51 pg/mL after 1 week.
4 | DISCUSSION
Recent data suggest that severe COVID‐19 causes cytokine release
storm and it is associated with worse clinical outcomes.10 IL‐6 plays a
pivotal role in this clinical scenario. In fact, in COVID‐19 patients
treated with tocilizumab, IL‐6 levels are significantly elevated, which
are supportive of the cytokine storm.11 It is plausible that blocking
IL‐6 resulted in the improvement of this hyperinflammatory state,
especially in patients with baseline higher levels of IL‐6.7,9,12 Ongoing
randomized control trials will allow for further evaluation of this
promising therapy. It is known that following initiation of tocilizumab,
there is an elevation in the IL‐6 levels due to saturation of the IL‐6
receptors by the drug.13 The results herein reported are in line with a
F IGURE 1 On a logarithmic scale, this figure reports the value of interleukin‐6 (IL‐6), C‐reactive protein (CRP), and procalcitonin (PCT) over
time in survivors (A) and nonsurvivors (B) as median. Below the graphs, the median and the number of available observations at each time are
indicated. For completeness, the interquartile ranges [25%‐75% IQR], which have been omitted in the figure, are as follows: for survivors (A),
baseline IL‐6 (pg/mL): 63.5 [52.2‐136], IL‐6 24 to 48 hours: 290.5 [76.7‐1119.7], IL‐6 week 2: 76.5 [47‐198.75], IL‐6 week 4: 116 [66‐124];
baseline CRP (mg/L): 150.6 [66.5‐210], CRP 24 to 48 hours: 41.3 [26.9‐63.8], CRP week 2: 4.4 [1.5‐6.4], CRP week 4: 1.6 [0.2‐5.1]; baseline PCT
(ng/mL): 0.14 [0.08‐0.28], PCT 24 to 48 hours: 0.06 [0.04‐0.09], PCT week 2: 0 [0‐0.04], PCT week 4: 0.03 [0‐0.04]. For nonsurvivors (B), baseline
IL‐6 (pg/mL): 171 [51‐523.5], IL‐6 24 to 48 hours: 2398.5 [594‐6819.7], IL‐6 week 2: 579 [338‐820], IL‐6 week 4: 146 [80‐212]; baseline CRP
(mg/L): 158 [116‐255.5], CRP 24 to 48 hours: 91.7 [54.5‐116.5], CRP week 2: 6.8 [3.9‐160.6], CRP week 4: 68.9 [60.9‐77]; baseline PCT (ng/mL):
0.28 [0.09‐0.46], PCT 24 to 48 hours: 0.37 [0.36‐1.01], PCT week 2: 0.15 [0.09‐0.63], PCT week 4: 0.22 [0.14‐0.29]
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recent published individual patient data systematic review that
summarized the baseline characteristics and clinical outcomes of
COVID‐19 patients who received tocilizumab.11 The increase of IL‐6,
as well as the dramatic changes of other laboratory features, seem to
characterize the subset of patients carrying the highest risk of
death.9,12
In addition, the present study preliminarily demonstrated, with
an appropriate follow‐up and methodology,7 that this early elevation
is significantly higher in patients showing the worst outcome than in
patients who recovered. Luo et al14 previously reported a similar
clinical observation in a smaller cohort of patients, in which all the
three patients who died showed increasing levels of serum IL‐6 after
tocilizumab until death. It may be argued that in older people there is
a dysregulated innate immunity and damage from too much IL‐6,15
even if the virus is killed. However, nonsurvivors were not older than
survivors in this study, as well as in the study by Luo et al.15 CRP
values showed similar differences between survivors and non-
survivors as seen for IL‐6, even if less significant. Nonsurvivors
showed a less clear reduction in CRP levels, and interestingly, pro-
calcitonin appeared not to decrease after tocilizumab. Tocilizumab
increases the risk of secondary infections, as other biological agents
do,16 and it could mask infections by inhibiting CRP production.17
Importantly, procalcitonin, as well as white blood cell count, did not
differ between the two groups, thus the higher levels of IL‐6 or CRP
in nonsurvivors were unlikely secondary to a superimposed sepsis,
while they probably mirror a higher hyperinflammatory state, and
may support the hypothesis of an intrinsically more resistant disease
in a subset of patients.7 In fact, in an autoinflammatory disease such
as Adult Onset Still's Disease, that similarly shows high levels of IL‐6
and IL‐1, procalcitonin can increase in the absence of any infection.18
The absence of differences in the baseline clinical features and in the
therapeutic approach between the two groups further support this
observation. Furthermore, patients at a higher risk of death may
produce the highest levels of IL‐6, and tocilizumab, by rapidly sa-
turating IL‐6 receptors, may reveal the greatest amount of circulating
IL‐6 in those patients. Thus, monitoring IL‐6 serum levels soon after
tocilizumab may be of major value in COVID‐19 pneumonia evolving
into cytokine storm syndrome, as this feature could support clinicians
in the difficult choice of continuing to target IL‐6 soon after the first
tocilizumab administration. Notably, transient elevated IL‐6 levels
have been implicated in Chimeric Antigen Receptor (CAR) neuro-
toxicity, which can occur independently from Cytokine Release
Syndrome (CRS).19 Thus, a second infusion of tocilizumab might be
hazardous, while other strategies targeting IL‐6, which are currently
under evaluation in clinical trials,20 might be more suitable. Siltux-
imab is a monoclonal antibody directly targeting IL‐6 and the
siltuximab‐IL‐6 complex is unlikely to cross the blood brain barrier.
Thus, it may be a safer choice as second‐line treatment targeting IL‐6
after tocilizumab in COVID‐19.19
The serum IL‐6 cut‐off value of 442.5 pg/mL appeared to best
differentiate survivors and nonsurvivors. The open question whether
a second infusion of tocilizumab, as in the case herein reported,
following the protocol for CAR T Cell‐induced CRS, is better than
using other drugs directly targeting IL‐6, such as siltuximab, needs to
be addressed.
This study has some limitations: first, the retrospective nature,
secondly, the absence of corrections for confounding factors and the
small number of patients included; therefore, it needs confirmation
by larger studies, and a more precise definition of the cut‐off value of
serum IL‐6.
To conclude, though preliminary, this study may provide a useful
indication for clinicians who are facing the most serious complication
of COVID‐19. Repeated measurement of serum level of IL‐6 early
after tocilizumab may identify patients carrying the highest risk of
death and possibly support the choice of further indirectly or directly
targeting IL‐6 to deeper reduce the hyperinflammatory state. Ran-
domized studies by stratifying patients according to different levels
of inflammatory state would be more insightful regarding the ther-
apeutic effect and the best schedule of tocilizumab in this setting.
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